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ABSTRACT 
Objectives 
To determine the clinical and cost-effectiveness of including emollient bath additives in the 
management of childhood eczema.  
Trial design  
Pragmatic randomised open-label superiority trial with two parallel groups. 
Setting and recruitment 
96 general practices in Wales, West of England and Southern England. Invitation by personal letter 
or opportunistically by usual clinical team. 
Participants  
Children were eligible to participate if aged over 12 months and less than 12 years, fulfilling UK 
Diagnostic Criteria for Atopic Dermatitis. Children with inactive or very mild eczema (5 or less on 
Nottingham Eczema Severity Scale) were excluded, as were children who bathed less than once a 
week, or whose carers were not willing to accept randomisation. 483 were randomised and one 
withdrew, leaving 482 children in the trial: 51% female, 84% white, mean age 5 years. 
Interventions  
The intervention group were prescribed emollient bath additives by their usual clinical team and 
were asked to use them regularly for 12 months. The control group were asked to use no bath 
additives for 12 months. Both groups continued with standard eczema management and were given 
standardised advice on how to wash. 
Primary outcome  
Eczema control measured by Patient Oriented Eczema Measure (POEM, range 0-28) weekly for 16 
weeks.  
Secondary outcomes 
Eczema severity over 1 year (4-weekly POEM from baseline to 52 weeks); number of eczema 
exacerbations resulting in primary healthcare consultation; disease-specific quality of life (QOL) 
(Dermatitis Family Impact); generic QoL (Child Health Utility-9D); resource utilisation; type and 
quantity of topical corticosteroid/calcineurin inhibitors prescribed. 
Randomisation  
483 children were randomised (1:1) using online software, stratified by recruiting centre. 
Results 
95.6% (461/482) of participants completed at least one post-baseline POEM, so were included in the 
analysis, and 76.8% (370/482) of participants completed questionnaires for more than 80% of the 
time points for the primary outcome (12/16 weekly questionnaires to 16 weeks).  
The mean Baseline POEM was 9.5 (s.d. 5.7) in the bath additives group and 10.1 (s.d. 5.8) in the no 
bath additives group. The mean POEM over the 16-week period was 7.5 (s.d. 6.0) in the bath 
additives group and 8.4 (6.0) in the no bath additives group. There was no statistically significant 
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difference in weekly POEM scores between groups over 16 weeks. After controlling for baseline 
severity and confounders (ethnicity, topical corticosteroid use, soap substitute use) and allowing for 
clustering of participants within centres and responses within participants over time, POEM scores in 
the no bath additive group were 0.41 points higher than in the bath additive group (95% CI -0.27 to 
1.10), below the published minimal clinically important difference for POEM of 3 points. 
There was no difference between groups in secondary outcomes, economic outcomes or in adverse 
effects. 
Conclusions  
This trial found no evidence of clinical benefit from including emollient bath additives in the 
standard management of childhood eczema. Further research is needed into optimal regimens for 
leave-on emollient and use of soap substitutes for children with eczema. 
Registered on 13th December 2013, ISRCTN: 84102309  
 
What this paper adds 
What is already known on this subject 
There are three methods of application of emollients: (1) leave-on emollients; (2) soap substitutes; 
and (3) emollient bath additives (oil and/or emulsifiers designed to be added to bath water).  
While there is evidence supporting the use of leave-on emollients and clinical consensus around 
soap substitutes, there is less agreement regarding the benefits of emollient bath additives for the 
treatment of childhood eczema. 
The effectiveness of emollient bath additives in the treatment of childhood eczema has not been 
assessed due to lack of adequately powered trials. 
 
What this study adds 
This is a large, pragmatic randomised controlled trial of children with eczema (aged 1 to 11 years) 
that recruited through primary care and followed up for 12 months. 
We found no evidence of clinically meaningful benefit from emollient bath additives, when used in 
addition to standard eczema management 
Questions remain about optimal regimens for leave-on treatments, soap substitutes and frequency 
of bathing in eczema. 
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INTRODUCTION 
Childhood eczema (synonyms atopic eczema, atopic dermatitis) is a common condition that can 
cause substantial impact on quality of life for both the child and their family.(1) Guidelines suggest 
that ‘complete emollient therapy’ form the mainstay of treatment for eczema and should be used 
regularly with topical corticosteroids/calcineurin inhibitors, used in addition for flare-ups.(2)  
Emollients are thought to act by providing a barrier over the skin, decreasing moisture loss and 
protecting against skin irritants. There are three methods of application: (1) leave-on emollients, 
where emollients are directly applied to the skin; (2) soap substitutes, where emollients are used 
instead of soap or other wash products; and (3) bath additives, which are oil and/or emulsifiers 
designed to be added to bath water and thought to leave a film of oil over the skin. Some emollients 
can be used in more than one way. We therefore use the term ‘emollient bath additives’ or ‘bath 
additives’ rather than ‘bath emollients’ in order to emphasise the differences between the three 
methods of application in recognition that products may have more than one method of application.  
While there is evidence for the need for leave-on emollients(3) and widespread clinical consensus 
around soap substitutes, there is less agreement regarding the potential additional benefits of bath 
additives (4) and there is a dearth of evidence of their effectiveness. Systematic reviews have found 
no evidence of their effectiveness and one small study suggested they may worsen eczema 
outcomes.(5) However, bath additives are widely prescribed at a cost of over £23 million per year to 
the NHS in England.(6) 
We sought to determine the clinical and cost-effectiveness of including emollient bath additives in 
the standard management of childhood eczema.  
 
METHODS 
This was a pragmatic, multicentre, randomised open-label superiority trial with two parallel groups 
allocated in a 1:1 ratio comparing emollient bath additives in addition to standard eczema care 
versus standard care alone for childhood eczema. We chose a pragmatic design (7) that aimed to 
test whether bath additives offer additional benefit in real life eczema care rather than in ideal 
experimental conditions. The study was registered before recruitment of the first participant, and 
the study protocol has been published.(8) BATHE was approved by the Newcastle & North Tyneside 
Research Ethics Committee 1 on 8th May 2014 (Ref: 14/NE/0098) 
Children eligible for the trial were aged over 12 months and less than 12 years and fulfilled UK 
Diagnostic Criteria for Atopic Dermatitis.(9) Children with inactive or very mild eczema over the last 
12 months were excluded, defined as a score of 5 or less on Nottingham Eczema Severity Scale (scale 
from 3 to 15, where 3 to 8 is mild; 9 to 11 is moderate; and 12 to 15 is severe).(10) Children who 
usually bathed less than once a week or whose carers were not willing to accept randomisation were 
also excluded. Only one child was enrolled per family. 
Participants were recruited from 96 general practices in Wales, West of England and Southern 
England. We used practices’ medical records to identify children who had a recorded diagnosis of 
eczema and who had obtained one or more prescriptions for eczema in the past 12 months. General 
practice staff also recruited potential participants opportunistically.  Parents/carers were asked to 
return a reply slip to the study team. A brief screening questionnaire included the UK Diagnostic 
Criteria for Atopic Dermatitis and the Nottingham Eczema Severity Scale. A researcher telephoned 
parents/carers who expressed an interest in the study to confirm likely eligibility and arrange a 
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baseline appointment at which time informed consent was sought and baseline questionnaires were 
completed. Subsequent questionnaires were completed online or by post with no further face-to-
face contact between the participants and the trial team. Informed consent was received for trial 
participants prior to enrolment. 
 
Interventions 
The intervention group were prescribed bath additives by their GP surgery and were asked to use 
them regularly for 12 months. We encouraged practices to issue the three bath additives most 
frequently prescribed in the UK: Oilatum (Glaxo SmithKline; 63% light liquid paraffin), Balneum 
(Allmarall Ltd.; 85% soya oil) or Aveeno (Johnson & Johnson Ltd; no Summary of Product 
Characteristics available). Other bath additives could be issued, with the exception of products 
containing antimicrobials, which were excluded as they have been shown to have greater irritant 
effect than other bath additives.(11) The control group were not prescribed bath additives and were 
asked not to use any bath additives for 12 months. Both groups were given standardised written 
advice on how to wash, including the use of leave-on emollient as soap substitute. Both groups were 
advised to continue with standard eczema management, including regular leave-on emollients and 
topical corticosteroids when required.  On-going clinical care was otherwise unchanged. 
 
Outcomes 
The primary outcome was eczema severity measured by Patient Oriented Eczema Measure (POEM) 
reported by parent/carer weekly over 16 weeks.(12, 13) The POEM is a patient-reported outcome 
which scores symptoms over the previous week. It consists of seven questions which can be 
completed by the child’s parent or carer and provides a severity score on a scale from 0 to 28, where 
0 to 2 is clear/almost clear; 3 to 7 is mild; 8 to 16 is moderate; and 17 to 28 is severe.(11) The 
published minimal clinically important difference of the POEM is 3 points.(14, 15)  POEM was the 
only patient-reported outcome measure for eczema to demonstrate validity and repeatability in a 
systematic review and has been adopted as the preferred patient-reported outcome measure for 
eczema symptoms internationally.(16, 17) 
The relapsing and remitting nature of eczema means that repeated measures is a better reflection of 
effect than follow-up assessment at a single timepoint.  
Secondary outcomes included  
• Eczema severity measured by POEM every 4 weeks from baseline to 52 weeks 
• Disease-specific quality of life at 16 weeks and 1 year, measured by Dermatitis Family 
Impact(18) 
• Generic quality of life at 16 weeks and 1 year, measured by Child Health Utility 9D(19) 
• Number of eczema exacerbations resulting in a primary healthcare consultation over 1 year 
(GP notes review) 
• Type (strength) and quantity of topical corticosteroid/calcineurin inhibitors prescribed over 
1 year (GP notes review) 
• Resource use from GP notes review and parent/carer questionnaires 
Other outcomes: 
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• Adherence to treatment allocation (parent/carer report) 
• Adverse effects, such as stinging, redness, slipping or bath refusal (parent/carer report) 
 
Sample size 
The sample size was calculated for repeated measures ANOVA in weekly POEM scores over 16 
weeks. Using weekly data from a similar population in the SWET trial(20) we aimed to detect a mean 
difference of 2.0 (s.d. 7.0) between intervention and control groups. Although the published minimal 
clinically important difference for POEM is 3,(14, 15) we sought to detect a difference of 2 due to the 
expectation of low POEM scores at baseline in a population recruited entirely through primary care.  
An alpha of 0.05 and power 0.9, with a correlation between repeated measures of 0.70, gave a 
sample size of 338. Allowing for 20% loss to follow-up gave a total sample size of 423 participants.  
Early data showed that approximately 80% of participants in both groups reported adherence to 
treatment allocation. Therefore, in order to allow a per protocol analysis with 90% power, in 
addition to the primary intention to treat analysis, we sought and obtained approval for an ethics 
amendment requesting permission to recruit an additional 68 participants, giving a revised target of 
491 participants. There were no other protocol changes. 
 
Randomisation 
Participants who provided consent were randomly allocated in 1:1 ratio to the intervention or 
control groups, stratified by co-ordinating centre (Southampton, Bristol, Cardiff). Randomisations 
were conducted at the end of the recruitment appointment, following completion of consent and 
baseline questionnaire so that treatment allocation could not be known prior to study entry. 
Randomisation was carried out using LifeGuide software hosted at the University of Southampton 
and automated to ensure concealment. As baseline appointments were sometimes remote from 
internet access, a back-up randomisation system involved phoning the trial manager. Unique 
participant identifier was then entered into a spreadsheet that allocated treatment on a 1:1 ratio, 
stratified by co-ordinating centre, from a MS Excel spreadsheet pre-programmed by the Trial 
Statistician. 30 randomisations were conducted using this offline method. 
 
It was not possible to make a convincing placebo for emollient bath additives, which add a greasy 
film to water, and participating families were therefore not blind to treatment allocation. As all 
outcomes were either participant-reported or collected on clinical record review template, we did 
not mask Clinical Study Officers/Research Nurses to allocation. Statisticians carrying out the analyses 
were blind to treatment allocation. 
 
Statistical methods 
Analysis was conducted according to CONSORT guidelines, following an analysis plan agreed in 
advance with the independent Trial Steering/Data monitoring Committee. We used descriptive 
statistics to compare baseline characteristics of trial participants by allocated group. The primary 
analysis for the total POEM score was performed using a multilevel mixed model framework with 
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observations over time from weeks 1 through to 16 (level 1) nested within participants (level 2).  Our 
primary outcome is based on adjusted results, controlling for baseline POEM, recruiting centre and 
any significant confounders. We also report unadjusted results. 
For all models, participants were analysed in the group to which they were randomised, regardless 
of their adherence to that allocation (intention to treat analysis).  The only exception to this was the 
per-protocol analysis, where analyses were carried out on the basis of bath additive use as reported 
by parent/carer.   
The model used all the observed data and made the assumption that missing POEM scores are 
missing at random given the observed data.  The model included a random effect for centre (random 
intercept) and patient (random intercept and slope on time) to allow for between-patient and 
between-centre differences at baseline and between-patient differences in the rate of change over 
time (if a treatment/time interaction was significant), and fixed effects for baseline covariates. An 
unstructured covariance matrix was used.  
For the analysis of secondary outcomes, repeated measures analysis in line with that used for the 
primary outcome was used for the monthly POEM measure up to 1 year. For other secondary 
outcomes, linear regression was used for continuous outcomes if the assumptions were met. 
Otherwise non-parametric analyses were used. Logistic regression was used for dichotomous 
outcomes and a suitable count model, as determined by goodness of fit measures, for count data. All 
analyses controlled for stratification variables and potential confounders.  Pre-planned sensitivity 
analysis and exploratory subgroup analyses were carried out as set out in the Statistical Analysis 
Plan. The economic evaluation used resource use, cost and effectiveness data collected from 
participants and GP notes review. 
 
Patient and public involvement (PPI) 
The James Lind Alliance Priority Setting Partnership for Eczema top 10 included priorities around 
bathing/washing and around the best ways to use emollients.(21) This trial was funded by NIHR 
Health Technology Assessment commissioned call following a topic suggestion form submitted 
through their website.  
The trial management group included an experienced PPI co-applicant (AR) who participated in all 
phases of trial design, including planning recruitment and recruitment materials. Members of the 
Centre of Evidence Based Dermatology Patient Panel were also consulted at trial design stage and 
additional PPI representation was also sought when planning how to disseminate findings. The 
independent trial steering committee included a PPI member. 
The results will be emailed to all trial participants and published on the trial website. 
The burden of the intervention was minimal, with many families already familiar with using bath 
additives with no difficulty. 
RESULTS 
Participants were recruited between December 2014 and May 2016. Invitations were sent to the 
parents/carers of 12,504 children and 1,451 responses were received. Of these, 920 expressed a 
willingness to be contacted and included a completed screening questionnaire. 662 met eligibility 
criteria and were approached regarding participation and 483 entered the trial. One carer 
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subsequently withdrew permission so analysis was carried out on data from 482 participants (n = 
264 intervention group, n = 218 control group) (see Figure 1). 
Table 1 shows the characteristics of participants in the trial. It can be seen that they were well 
balanced at baseline, although there were more participants allocated to the bath additive group 
than the no bath additive group. 
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Figure 1:  
 
  
Assessed for eligibility
(n = 1,447)
Usual Care WITH 
Bath Additive 
(n = 265)
Usual Care NO 
Bath Additive
(n = 218)
 Analysed (n = 252)  Analysed (n = 209)
Lost to follow-up (n = 13)
Completed no post-baseline 
measures (n = 12 )
Withdrawn, remove all data (n = 1)a
Randomised 
(n = 483)
Invited
(n = 12,504)
Excluded (n=964)
Declined to participate (n = 527)
Did not meet inclusion criteria (n = 200)
Other reasons (n = 237)
Lost to follow-up (n = 9)
Completed no post-baseline 
measures (n = 9)
Withdrawn (n = 0)
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Table 1: Baseline characteristics of trial participants 
 Bath additive 
(n=264) 
No bath additive 
(n=218) 
Total 
(n =482 ) 
Child age (years)    
Mean (s.d.) 5.4 (2.9) 5.2 (2.9) 5.3 (2.9) 
Child gender     
Male 138/264 (52.3%) 100/218 (45.9%) 238/482 (49.4%) 
Female 126/264 (47.7%) 118/218 (54.1%) 244/482 (50.6%) 
Carer age (years)    
Mean (s.d.) 36.5 (6.5) 35.9 (6.7) 36.2 (6.5) 
Carer gender     
Male 11/258 (4.3%) 12/212 (5.7%) 23/470 (4.9%) 
Female 247/258 (95.7%) 200/212 (94.3%) 447/470 (95.1%) 
Ethnicity     
White 228/257 (86.0%)         176/215 (81.9%) 397/472 (84.1%) 
Black 6/257 (1.9%) 9/215 (4.2%) 15/472 (3.2%) 
Asian 
Mixed race 
Chinese 
Other 
15/257 (5.8%) 
10/257 (3.9%) 
2/257 (0.8%) 
3/257 (1.2%) 
16/215 (7.4%) 
9/215 (4.2%) 
3/215 (1.4%) 
2/215 (0.9%) 
31/472 (6.6%) 
19/472 (4.0%) 
5/472 (1.1%) 
5/472 (1.1%) 
Highest qualification    
Not answered   6/257 (2.3%)        3/213 (1.4%) 9/470 (1.9%) 
Degree or equivalent 106/257 (41.3%)       90/213 (42.3%) 197/470 (41.7%) 
Diploma or equivalent 56/257 (21.8%)  37/213 (17.4%) 95/470 (19.8%) 
A-level      25/257 (9.7%)    24/213 (11.3%) 49/470 (10.4%) 
GSCE/O-level    50/257 (19.5%)          38/213 (17.8%) 88/470 (18.7%) 
Other 12/257 (4.7%) 16/213 (7.5%) 29/470 (6.0%) 
None 2/257 (0.8%) 5/213 (2.4%) 7/470 (1.5%) 
Cost of Living    
Not answered     7/257 (2.7%)  3/213 (1.4%) 10/470 (2.1%) 
Finding it a strain 11/257 (4.3%) 3/213 (1.4%) 14/470 (3.0%) 
Have to be careful 105/257 (40.9%) 82/213 (38.5%) 187/470 (39.8%) 
Able to manage 99/257 (38.5%) 90/213 (42.3%) 189/470 (40.2%) 
Quite comfortable 35/257 (13.6%)  35/213 (16.4%) 70/470 (14.9%) 
    
Prior belief in bath additives (1-9)a   5.1 (2.2)  4.8 (2.3) 5.0 (2.3) 
    
POEM scores (0-28)    
Mean (sd) 9.5 (5.7) 10.1 (5.8) 9.8 (5.8) 
Mild (0-7) 114 (43.2%) 73 (33.5%) 187 (38.8%) 
Moderate (8-16) 119 (45.1%) 114 (52.3%) 233 (48.3%) 
Severe (17-28) 31 (11.7%) 31 (14.2%) 62 (12.9%) 
    
DFIQ score (0-30)    
Median (IQR) 2 (1,6) 3 (1,7) 3 (1,7) 
NESS score (3-15)    
Mean (sd)         9.5 (2.3) 9.5 (2.3)  9.5 (2.3)  
CHU-9D score (Utility values)    
Mean (sd) 0.90 (0.1) 0.90 (0.1) 0.90 (0.1) 
a where 1 is ‘not at all effective’ and 9 is ‘very effective’ 
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461/482 (95.6%) participants had completed at least one POEM following baseline and were 
included in the primary analysis, and 76.8% (370/482) completed more than 80% of the time points 
for the primary outcome (12/16 weekly questionnaires to 16 weeks).  
Parent/carer report of adherence to treatment allocation group at 16 weeks showed 92.7% 
(216/233) of participants in the bath additive group using bath additive ‘every time’ or ‘more than 
half the time’.  Similarly, 92.1% (176/191) of those in the no bath additive group said that they used 
bath additive either ‘never’ or ‘less than half the time’ (see table 2).   
Table 2: Adherence to allocated treatment and frequency of bathing during the 16-week primary 
outcome period 
 Bath additive  No bath additive  
Use of bath additives: (n=233) (n=191) 
Every time 172 (73.8%) 14 (7.3%) 
More than half the time 44 (18.9%) 1 (0.5%) 
Less than half the time 15 (6.4%) 9 (4.7%) 
Never 2 (0.9%) 167 (87.4%) 
   
Number of baths per week: (n=221) (n=176) 
1-2 70 (31.7%) 54 (30.7%) 
3-4 74 (33.5%) 56 (31.8%) 
5-6 45 (20.4%) 39 (22.2%) 
7 or more 32 (14.5%) 27 (15.3%) 
 
 
Parent/carer report regarding frequency of bathing were: 31.2% (124/397) fewer than three baths 
per week; 32.7% (130/397) three or four baths per week; 36.0% (143/397) 5 or more baths per 
week.  
Of participants allocated to receive bath additives, 45.2% (120/265) received Oilatum Junior bath 
additive, 25.7% (68/265) received Aveeno bath oil, 4.5% (12/265) received Balneum bath oil and 
29.8% (79/265) received an other bath additive. (14 received more than one different bath additive 
during the study). 
The Baseline POEM score was 9.5 (s.d. 5.7) in the bath additives group and 10.1 (s.d. 5.8) in the no 
bath additives group. The mean POEM score over the 16 week period was 7.5 (s.d. 6.0) in the bath 
additives group and 8.4 (6.0) in the no bath additives group. There was no statistically significant 
difference in weekly POEM scores between the two groups over the 16-week period. After 
controlling for baseline severity and confounders (ethnic group, topical corticosteroid use, and soap 
substitute use) and allowing for the clustering of participants within centres and responses within 
participants over time, the POEM score in the no bath additive group was 0.41 points higher than in 
the bath additive group (95% CI -0.27 to 1.10), which is substantially lower than the published 
minimal clinically important difference of 3 points.(14, 15) 
 
Figure 2: POEM scores during the 16-week primary outcome period 
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Secondary analyses looking at differences between groups based on adherence to treatment 
allocation (per protocol analysis) similarly showed no statistically significant difference between the 
groups on POEM 16 weeks repeated measures: ‘More than half’ or ‘every time’ vs. ‘less than half the 
time’ or ‘never’ adjusted difference in mean POEM 0.32 (95% CI -0.37 to 1.02). 
There were no significant differences between groups in any of the secondary outcomes, such as 
POEM over 52 weeks (adjusted difference in mean POEM 0.75 (95%CI -0.05 to 1.55), Dermatitis 
Family Impact, generic quality of life (Child Health Utility 9D), number of eczema exacerbations and 
type /quantity of topical corticosteroid/calcineurin inhibitors prescribed over 1 year. 
 
Table 3: Secondary outcomes by treatment allocation 
 
Bath additive 
Mean (s.d.) 
No bath 
additive 
Mean (s.d) 
Univariate 
difference in mean 
POEM (95% CI) 
Adjusted difference 
in mean POEM (95% 
CI) 
Monthly repeated 
measures 
    
Over the 52 week period 
(repeated measures) 
7.3 (6.3) 8.4 (6.4)  0.99 (0.03 to 1.96)    0.75 (-0.05 to 1.55)  
 
 
Secondary outcome – 
Disease-specific QOL 
Bath additive 
Median (IQR) 
No bath 
additive 
Median (IQR) 
Univariate 
difference in 
median DFIQ 
(95% CI) 
Adjusted difference 
in median DFIQ 
(95% CI) 
DFIQ at baseline 
DFIQ at 16 weeks 
DFIQ at 52 weeks 
2 (1,6) 
2 (0,5) 
2 (0,5) 
3 (1,7) 
3 (1,7) 
2 (0,6) 
 
1.00 (0.09 to 1.91)  
0.00 (-0.93 to 0.93) 
 
0.29 (-0.57 to 1.14)  
-0.29 (-1.36 to 0.79)  
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Secondary outcome –  
Generic QOL 
Bath additive 
Mean (s.d.) 
No bath 
additive  
Mean (s.d.) 
Univariate 
difference in mean 
(95% CI) 
 
CHU-9D at baseline 0.90 (0.1) 0.90 (0.1) 0.00 (-0.02 to 0.02)  
CHU-9D at 16 weeks 0.91 (0.1) 0.89 (0.1) 0.01 (-0.01 to 0.03)  
CHU-9D at 52 weeks 0.90 (0.1) 0.91 (0.1) -0.01 (-0.03 to 
0.01) 
 
 
Secondary outcome – 
quantity of TCS/TCI* 
prescribed 
    
Total number of TCS/TCI 
prescriptions 
Median number of 
TCS/TCI prescriptions 
325 
 
0 (0,2) 
346 
 
1 (0,3) 
  
 
Secondary outcome – 
Exacerbations   
Univariate RR 
exacerbations 
(95% CI) 
Adjusted RR (95% 
CI) 
Number of exacerbations  1 (0,2) 1 (0,3) 1.33 (1.02 to 1.75) 1.24 (0.96 to 1.60) 
     
*TCS/TCI denotes topical corticosteroid or topical calcineurin inhibitor 
 
Pre-specified exploratory subgroup analyses suggested the possibility of a small effect of bath 
additives amongst children aged less than 5 years, as the no bath additive group had a POEM score 
1.29 (95% CI 0.33 to 2.25) points higher than the group with bath additives.  However, the upper 
limit of the confidence interval is below the now widely accepted POEM minimal clinically important 
difference of 3 points. 
A significant interaction effect was also seen by frequency of bathing as reported at 16 weeks.  There 
was no statistically significant difference in those children who bathed 1 to 4 times per week.  
However, in those children who bathed 5 or more times per week, the POEM score was 2.27 points 
higher (95% CI 0.63 to 3.91) in the no bath additive group.  The upper confidence interval suggests 
there may be a small clinically meaningful benefit to bath additives in this group.  But this is group 
has only 77 in the bath additive group and 66 in the no bath additive group (See table 4). 
Interestingly, there was no apparent difference in outcomes for those with moderate or severe 
eczema. 
15 
 
Table 4: POEM scores during the 16-week primary outcome period, by group and subgroup 
Primary outcome – 16 week 
repeated measures N (%) 
Bath 
additive 
Mean (sd) 
No bath 
additive 
Mean (sd) Interaction term 
Adjusted 
difference in 
mean POEMa  
(95% CI) 
      
Age:    -1.43 (-2.02, -0.15)  
Below age 5 years 256 (53.1%) 6.99 (5.67) 9.09 (6.01)  1.29 (0.33, 2.25) 
Age 5+ years 226 (46.9%) 7.97 (6.24) 7.52 (5.92)  -0.29 (-1.21, 0.63) 
      
Baseline severity:    -0.05 (-1.14, 1.05)  
Clear/mild (0-7)  187 (38.8%) 4.78 (4.26) 5.22 (4.58)  -0.07 (-1.08, 0.95) 
Moderate (8-16)  233 (48.3%) 8.14 (5.54) 9.18 (5.46)  0.65 (-0.45, 1.74) 
Severe/very severe  62 (12.9%) 14.63 (6.16) 13.03 (6.92)  
-1.16 (-3.62, 1.32) 
      
Use of leave-on emollient:    -0.02 (-2.05, 2.01)  
0-4 days per week  138 (28.6%) 7.64 (6.68) 6.43 (5.42)  0.26 (-1.34, 1.86) 
5-7 days per week  344 (71.4%) 8.61 (5.74) 7.93 (6.14)  0.69 (-0.39, 1.76) 
      
Topical corticosteroid use:    0.52 (-1.35, 2.40)  
Any  241 (50.7%) 8.40 (6.19) 9.35 (6.21)  1.22 (-0.18, 2.63) 
None  234 (49.3%) 6.63 (5.64) 7.39 (5.66)  0.58 (-0.64, 1.81) 
      
Frequency of bathing at 16 
weeks: 
   2.14 (0.21, 4.07)  
1-4 times per week 255 (64.1%) 7.93 (5.94) 8.00 (5.82)  -0.26 (-1.38, 0.87) 
5+ times per week 143 (35.9%) 6.30 (5.70) 8.75 (6.12)  2.27 (0.63, 3.91) 
      
Prior belief in bath additive:    0.85 (-0.52, 2.21)  
1-3 low belief 106 (29.4%) 7.93 (6.10) 9.27 (6.25)  1.17 (-0.78, 3.13) 
4-6 moderate belief 158 (43.8%) 8.37 (6.06) 8.68 (6.02)  -0.16 (-1.77, 1.45) 
7-9 high belief 97 (26.9%) 5.70 (5.06) 7.09 (6.05)  1.80 (0.04, 3.56) 
      
Use of soap substitute at 16 
weeks: 
   1.30 (-0.97, 3.57)  
Any  89 (20.8%) 8.09 (6.10) 9.31 (5.88)  1.72 (-0.44, 3.88) 
None  340 (79.3%) 7.17 (5.82) 7.99 (5.87)  0.36 (-0.63, 1.35) 
a  Adjusted for baseline severity, ethnic group, steroid use and soap substitute use and allowing for the 
clustering of patients within centres and responses within patients over time 
 
Adverse effects were remarkably similar in both groups, despite slips in the bath, stinging or redness 
being common side effects reported in Summary of Product Characteristics for emollient bath 
additives. Over the first 16 weeks, 34.5% in the bath additive group and 35.4% in the no bath 
additive group reported at least one adverse event on weekly questionnaires (Table 5), with no 
statistically significant difference between the groups (OR 1.40 95% CI 0.79 to 2.47).   
Table 5: Adverse events by treatment allocation 
Adverse events – over 16 weeks Bath additive (n=252) No bath additive (n=209) 
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Slips 
Stinging 
Redness 
Refuses a bath 
44 (17.5%) 
4 (1.6%) 
35 (13.9%) 
21 (8.3%) 
52 (24.8%) 
4 (1.9%) 
48 (23.0%) 
25 (12.0%) 
Adverse events – over 52 weeks Bath additive (n=252) No bath additive (n=209) 
Slips 
Stinging 
Redness 
Refuses a bath 
56 (22.2%) 
7 (2.8%) 
44 (17.5%) 
30 (11.9%) 
63 (30.1%) 
4 (1.9%) 
61 (29.2%) 
31 (14.8%) 
 
The economic evaluation followed a pre-specified analysis plan and explored resource utilisation 
from the health system (NHS) and family perspective. The mean annual costs to the NHS were 
estimated at £180.50 (s.d. 237.0) for the bath additives group and £166.12 (s.d. 293.0) for the no 
bath additives group. Similarly, the annual results for QALYs were 0.91 (s.d. 0.1) and 0.90 (s.d. 0.1) 
for the bath additives and the no bath additives group respectively. The difference in cost means 
was £14.38 (95% CI -33.45 to 62.21) and in QALY means was 0.00 (95% CI -0.01 to 0.02). The family-
borne costs showed an annual higher spend within the no bath additives group of £51.37 (95% CI  -
15.74 to 118.49) and the adjusted difference was £47.56 (95% CI -18.07 to 113.19), none statistically 
significant.  The economic analysis found no benefits that could be used to consider the intervention 
cost-effective. Full data on resource use (GP notes review and parent/carer report) and cost-
effectiveness analysis will be published in the NIHR HTA journals library. 
 
DISCUSSION 
This trial provides strong evidence that emollient bath additives provide minimal or no additional 
benefit beyond standard eczema care in the management of childhood eczema.  
The BATHE trial was an adequately powered trial, with high follow-up rates and good adherence to 
trial intervention allocations. The study has strong external validity as it was pragmatic in design to 
reflect normal practice, and, despite the relatively low response rate, participants were broadly 
reflective of children with eczema seen in primary care. We used a participant-reported outcome 
measure with good validity that has been accepted by international consensus.(15) A participant-
reported outcome could be biased in favour of finding a positive effect of trial intervention due to a 
perception of benefits of treatment. However, the negative result of the trial suggests that this was 
not the case. 
This is the largest trial on the role of emollient bath additives to date and previous reviews of the 
literature have not been able to draw conclusions from existing small trials.(5)   
We cannot exclude the possibility of a small benefit amongst children bathing more than 5 times per 
week or amongst children aged less than 5 years but differences are sufficiently small to be unlikely 
to be clinically useful. Furthermore, caution is needed in interpreting these underpowered subgroup 
analyses as statistically significant results may arise because the data has been tested multiple times 
rather than because a genuine difference exists between the groups.   
These findings are timely for clinicians and prescribing advisers, as prescribing guidelines vary widely 
in their advice regarding bath additive use(22)  and pressure on budgets have led to formularies 
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becoming increasingly restrictive. Reviews have estimated that bath additives may contribute to up 
to a third of the costs of eczema in the UK.(4) Our findings provide evidence that can contribute to 
effective prescribing in this area, where there is currently very little research evidence to guide 
decision-making. These findings are also useful for families with eczema as they have more certainty 
about directing their efforts towards more effective treatments. 
Our findings are only relevant to the use of emollient bath additives. More research is needed into 
optimal regimens for other emollients, although there is strong evidence that regular use of leave-on 
emollients prevents flare-ups in eczema(3) and there is widespread clinical consensus around the 
role of emollients as soap substitutes.  
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